Samuel F. Lockwood
Former positions of Samuel F. Lockwood
| Companies | Position | End |
|---|---|---|
Cardax Pharma, Inc.
 Cardax Pharma, Inc. Pharmaceuticals: MajorHealth Technology Part of Cardax, Inc., Cardax Pharma, Inc. is a pharmaceutical company that previously focused on developing a platform of proprietary, exceptionally safe, small molecule compounds for large unmet medical needs where oxidative stress and inflammation play key causative roles. The company is based in Honolulu, HI. The company may seek to monetize its pharmaceutical assets through licensing or sale. Astaxanthin use is supported by hundreds of peer-reviewed papers published in leading medical research journals. The company was founded by David G. Watumull, Samuel F. Lockwood, and David G. Watumull has been the CEO since incorporation. Cardax Pharma was acquired by Koffee Korner, Inc. on February 07, 2014 for $15 million. | Founder | - |
Hawaii Biotech, Inc.
 Hawaii Biotech, Inc. Pharmaceuticals: OtherHealth Technology Hawaii Biotech, Inc. operates as a biotechnology company that focuses on the research and development of vaccines for established and emerging infectious diseases. It has developed proprietary expertise in the production of recombinant proteins applicable to the development of safe and effective vaccines. The firm's products include anti-toxin drugs for the lethal factor from B. anthracis and the botulinum toxin from C. botulinum. The company was founded in 1982 and is headquartered in Honolulu, HI. | Corporate Officer/Principal | - |
Training of Samuel F. Lockwood
| University of Dayton | Undergraduate Degree |
| Texas A&M University | Graduate Degree |
| The University of Texas at Austin | Doctorate Degree |
Experiences
Positions held
Linked companies
| Private companies | 2 |
|---|---|
Hawaii Biotech, Inc.
Hawaii Biotech, Inc. Pharmaceuticals: OtherHealth Technology Hawaii Biotech, Inc. operates as a biotechnology company that focuses on the research and development of vaccines for established and emerging infectious diseases. It has developed proprietary expertise in the production of recombinant proteins applicable to the development of safe and effective vaccines. The firm's products include anti-toxin drugs for the lethal factor from B. anthracis and the botulinum toxin from C. botulinum. The company was founded in 1982 and is headquartered in Honolulu, HI. | Health Technology |
Cardax Pharma, Inc.
Cardax Pharma, Inc. Pharmaceuticals: MajorHealth Technology Part of Cardax, Inc., Cardax Pharma, Inc. is a pharmaceutical company that previously focused on developing a platform of proprietary, exceptionally safe, small molecule compounds for large unmet medical needs where oxidative stress and inflammation play key causative roles. The company is based in Honolulu, HI. The company may seek to monetize its pharmaceutical assets through licensing or sale. Astaxanthin use is supported by hundreds of peer-reviewed papers published in leading medical research journals. The company was founded by David G. Watumull, Samuel F. Lockwood, and David G. Watumull has been the CEO since incorporation. Cardax Pharma was acquired by Koffee Korner, Inc. on February 07, 2014 for $15 million. | Health Technology |
- Stock Market
- Insiders
- Samuel F. Lockwood
